Retrospective study finds 15.1% incidence of atrial fibrillation in ibrutinib-treated patients, suggesting cardiovascular risk monitoring is essential.
Key Points
Patients treated with ibrutinib had a 15.1% incidence of atrial fibrillation after a median of 33.5 months.
Older patients and those with higher cardiovascular risk factors were more likely to develop atrial fibrillation.
Retrospective analysis of 93 patients treated with ibrutinib from 2010 to 2024 provided insights into risk factors for atrial fibrillation.
Those developing atrial fibrillation required cautious management strategies, emphasizing the significance of cardiac monitoring.